The latest price target for VBI Vaccines (NASDAQ:VBIV) was reported by Raymond James on April 13, 2023. The analyst firm set a price target for $6.00 expecting VBIV to rise to within 12 months (a possible 700.00% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for VBI Vaccines (NASDAQ:VBIV) was provided by Raymond James, and VBI Vaccines maintained their outperform rating.

There is no last upgrade for VBI Vaccines

The last downgrade for VBI Vaccines Inc happened on November 11, 2022 when Raymond James changed their price target from $5 to $2 for VBI Vaccines Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VBI Vaccines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VBI Vaccines was filed on April 13, 2023 so you should expect the next rating to be made available sometime around April 13, 2024.

While ratings are subjective and will change, the latest VBI Vaccines (VBIV) rating was a maintained with a price target of $60.00 to $6.00. The current price VBI Vaccines (VBIV) is trading at is $0.75, which is out of the analyst’s predicted range.